You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK)年度純利大增1436.7%至19.87億港元 末期息3.1港仙
格隆匯 03-29 16:42

格隆匯3月29日丨李氏大藥廠(00950.HK)發佈公吿,截至2021年12月31日止12個月,實現收益12.66億港元,同比增長4.1%;毛利8.06億港元,同比增長3.2%;公司擁有人應占溢利19.87億港元,同比增長1436.7%;基本每股盈利337.58港仙,擬派末期股息每股普通股3.1港仙。

年內,集團錄得收益12.66億港元,按年增長4.1%。引進產品的銷售額為7.49億港元,佔集團收益的59.2%,而專利及仿製產品的銷售額則為5.17億港元,佔集團收益的40.8%。

引進產品的銷售額方面,由於長期病患藥物需求不受影響,故《可益能》®錄得不錯的增長,為15.0%;《菲普利》®通過品牌轉型、進軍非處方藥物領域,取得強勁增長,為29.1%;《蓋世龍》®及《善可舒》®等其他產品亦於報吿年度帶來收益增長貢獻;而於2021年第三季度新推出的布累迪寧亦貢獻約2.8%的收益。因此,儘管《再寧平》®中國特許授權終止而喪失收益,惟引進產品的銷售額仍較去年增長10.5%。

作為集團首隻仿製產品,曲前列尼爾注射液較去年顯著增長87.3%。另外兩隻仿製產品磺達肝癸鈉注射液及苯丁酸鈉顆粒亦於報吿年度內開始帶來收益貢獻。至於來自專利產品的銷售額,《尤靖安》®通過品牌轉型、進軍非處方藥物領域,取得強勁增長,為51.2%;而《速樂涓》®則穩步增長5.5%。然而,此等銷售額增幅只能部分抵銷因《立邁青》®作為那屈肝素鈣注射液重新安排在醫院上市,令市場受干擾而喪失的收益。專利產品及仿製產品總銷售額較去年減少4.0%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account